Fresenius Kabi Takes Control Of mAbxience To Bolster Biosimilars
Also Announces Acquisition Of Ivenix To Strengthen Medtech Business
• By David Wallace
The deal for a 55% stake in mAbxience includes a put/call option scheme for the remaining 45% • Source: christitzeimaging.com / Alamy Stock Photo 
